ARCHIVES

Clinical Trials Approved By NCI In November

This article is from The Cancer Letter archive.

Vol. 24 No. 12 | December 28, 2001

Download PDF Visit The Full Archive

Related Articles

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012

Letter: Headline Criticized On Letter About Consortium

June 21, 1996

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status

November 28, 1975

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002

New Tool Found To Cut DNA At Any Position

April 4, 1986